Schwann Cells and Their Exosomes: Research Progress and Prospect in Spinal Cord Injury
Wang X., Yan W., Zhu L., Wei L., Cao H., Yang F.
Narrative Review on Spinal Cord Injury, Scar, Chronic Inflammation, Immune Modulation, published in Neural Plast (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Neural Plast (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40548333
- PMCID
- PMC12178780
- DOI
- 10.1155/np/6684089
Abstract (original English)
Spinal cord injury (SCI) is a severe condition that affects the central nervous system (CNS), for which there is currently no effective treatment. Schwann cells (SCs) transplantation for SCI has been well demonstrated in preclinical studies, showing that it can achieve therapeutic goals by improving autonomic function, reducing neuropathic pain, and enhancing limb function through mechanisms such as alleviating inflammation, modulating immunity, and reducing dense scar formation. However, the transplantation of SCs sometimes encounters adverse events, such as low survival rates, significant rejection reactions, limitations on transplantation methods, and the formation of glial scars, all of which severely hinder its clinical application. Meanwhile, SC-derived exosomes (SC-exos) also hold great potential in treating SCI, with specific roles, including immune modulation, anti-inflammatory effects, angiogenesis, apoptosis inhibition, and promotion of axonal regeneration, even surpassing traditional cell therapy in certain aspects. This paper aims to elucidate the potential mechanisms and valuable therapeutic roles of SCs and SC-exos in the treatment of SCI, as well as to provide insights for subsequent research directions by analyzing their current limitations.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci